Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Melphalan based autologous transplant in octogenarian multiple myeloma patients.

Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH.

Am J Hematol. 2018 Oct 9. doi: 10.1002/ajh.25310. [Epub ahead of print] No abstract available.

PMID:
30300461
2.

Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease in North America.

Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ.

Biol Blood Marrow Transplant. 2018 Oct 5. pii: S1083-8791(18)30607-4. doi: 10.1016/j.bbmt.2018.09.040. [Epub ahead of print]

PMID:
30296479
3.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2018 Aug 25. pii: S1083-8791(18)30489-0. doi: 10.1016/j.bbmt.2018.08.018. [Epub ahead of print]

PMID:
30153491
4.

A phase II/III randomized, multicenter trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for treatment of chronic graft-versus-host disease: BMT CTN 0801.

Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; Blood and Marrow Clinical Trials Network.

Haematologica. 2018 Jun 28. pii: haematol.2018.195123. doi: 10.3324/haematol.2018.195123. [Epub ahead of print]

5.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW.

Blood Adv. 2018 May 8;2(9):1022-1031. doi: 10.1182/bloodadvances.2017013052. Erratum in: Blood Adv. 2018 Jun 12;2(11):1294.

6.

Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay.

Abram TJ, Pickering CR, Lang AK, Bass NE, Raja R, Meena C, Alousi AM, Myers JN, McDevitt JT, Gillenwater AM, Vigneswaran N.

Transl Oncol. 2018 Apr;11(2):477-486. doi: 10.1016/j.tranon.2018.01.014. Epub 2018 Feb 24.

7.

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.

Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1514-1520. doi: 10.1016/j.bbmt.2018.02.003. Epub 2018 Feb 12.

PMID:
29448058
8.

Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.

Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K.

Front Immunol. 2018 Jan 12;8:1937. doi: 10.3389/fimmu.2017.01937. eCollection 2017.

9.

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1274-1280. doi: 10.1016/j.bbmt.2018.01.002. Epub 2018 Jan 8.

PMID:
29325830
10.

Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.

Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM.

Bone Marrow Transplant. 2018 Mar;53(3):315-325. doi: 10.1038/s41409-017-0034-z. Epub 2017 Dec 21.

PMID:
29269797
11.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

12.

Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.

Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2166-2171. doi: 10.1016/j.bbmt.2017.08.021. Epub 2017 Aug 24.

PMID:
28844946
13.

Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.

Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM.

Am J Surg Pathol. 2017 Nov;41(11):1483-1490. doi: 10.1097/PAS.0000000000000914.

PMID:
28834808
14.

Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.

Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL Jr, Khouri IF.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1405-1410. doi: 10.1016/j.bbmt.2017.04.027. Epub 2017 May 8.

15.

B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Saliba RM, Sarantopoulos S, Kitko CL, Pawarode A, Goldstein SC, Magenau J, Alousi AM, Churay T, Justman H, Paczesny S, Reddy P, Couriel DR.

Bone Marrow Transplant. 2017 Jul;52(7):1010-1015. doi: 10.1038/bmt.2017.73. Epub 2017 May 8.

16.

Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma.

Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1059-1063. doi: 10.1016/j.bbmt.2017.03.030. Epub 2017 Apr 4.

17.

Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.

Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR, van den Brink MRM.

J Clin Oncol. 2017 May 20;35(15):1650-1659. doi: 10.1200/JCO.2016.70.3348. Epub 2017 Mar 15.

18.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO.

Am J Hematol. 2017 Apr;92(4):331-337. doi: 10.1002/ajh.24632. Epub 2017 Feb 13.

19.

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.

Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE.

Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18.

20.

IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K.

Blood. 2016 Sep 8;128(10):1346-61. doi: 10.1182/blood-2016-01-695122. Epub 2016 Jul 20.

21.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

22.

The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.

Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA.

Cancer. 2016 Jul 15;122(14):2186-96. doi: 10.1002/cncr.30039. Epub 2016 May 3.

23.

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1333-1337. doi: 10.1016/j.bbmt.2016.03.028. Epub 2016 Apr 6.

24.

Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.

Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U.

Bone Marrow Transplant. 2016 Jul;51(7):999-1001. doi: 10.1038/bmt.2016.28. Epub 2016 Mar 7. No abstract available.

PMID:
26950376
25.

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolaños-Meade J, Alousi AM, Ferrara JL; Blood and Marrow Transplant Clinical Trials Network.

Lancet Haematol. 2015 Jan;2(1):e21-9. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.

26.

Umbilical cord blood graft engineering: challenges and opportunities.

Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S55-62. doi: 10.1038/bmt.2015.97. Review.

PMID:
26039209
27.

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1776-82. doi: 10.1016/j.bbmt.2015.05.023. Epub 2015 May 30.

28.

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE.

Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7.

29.

Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.

Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF.

Biol Blood Marrow Transplant. 2015 May;21(5):855-9. doi: 10.1016/j.bbmt.2015.01.013. Epub 2015 Jan 31.

30.

Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.

Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME.

Biol Blood Marrow Transplant. 2015 Apr;21(4):640-5. doi: 10.1016/j.bbmt.2014.10.022. Epub 2014 Dec 18.

31.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT.

Blood. 2014 Nov 20;124(22):3221-7; quiz 3335. doi: 10.1182/blood-2014-06-577023. Epub 2014 Aug 28.

32.

Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.

Ma Q, Li D, Carreño R, Patenia R, Tsai KY, Xydes-Smith M, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan V.

Bone Marrow Transplant. 2014 Jul;49(7):972-6. doi: 10.1038/bmt.2014.75. Epub 2014 Apr 28.

33.

Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Hart JW, Shiue LH, Shpall EJ, Alousi AM.

Ther Adv Hematol. 2013 Oct;4(5):320-34. doi: 10.1177/2040620713490316.

34.

Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function.

Dhamne C, Chung Y, Alousi AM, Cooper LJ, Tran DQ.

Front Immunol. 2013 Aug 27;4:253. doi: 10.3389/fimmu.2013.00253. eCollection 2013.

35.

Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.

Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF.

Cancer. 2013 Sep 15;119(18):3318-25. doi: 10.1002/cncr.28219. Epub 2013 Jun 17.

36.

Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease.

Shiue LH, Alousi AM, Wei C, Hosing CM, Duvic M, Ni X.

J Invest Dermatol. 2013 Aug;133(8):2098-100. doi: 10.1038/jid.2013.142. Epub 2013 Mar 21. No abstract available.

37.

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U.

Biol Blood Marrow Transplant. 2013 Jun;19(6):991-4. doi: 10.1016/j.bbmt.2013.03.008. Epub 2013 Mar 16.

38.

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE.

Blood. 2013 Mar 28;121(13):2567-73. doi: 10.1182/blood-2012-08-453860. Epub 2013 Jan 29.

39.

Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.

Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5. doi: 10.1016/j.bbmt.2012.12.003. Epub 2012 Dec 12.

40.

Graft-versus-host disease: state of the science.

Alousi AM, Bolaños-Meade J, Lee SJ.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S102-8. doi: 10.1016/j.bbmt.2012.10.028. Epub 2012 Oct 27. Review. No abstract available.

41.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA.

Blood. 2012 Jun 28;119(26):6373-8. doi: 10.1182/blood-2012-03-417808. Epub 2012 May 14.

42.

Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Hymes SR, Alousi AM, Cowen EW.

J Am Acad Dermatol. 2012 Apr;66(4):535.e1-16; quiz 551-2. doi: 10.1016/j.jaad.2011.11.961.

PMID:
22421124
43.

Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Hymes SR, Alousi AM, Cowen EW.

J Am Acad Dermatol. 2012 Apr;66(4):515.e1-18; quiz 533-4. doi: 10.1016/j.jaad.2011.11.960.

PMID:
22421123
44.

Making the diagnosis of gastrointestinal GVHD: is evaluation of the ileum necessary?

Ross WA, Alousi AM.

Bone Marrow Transplant. 2012 Mar;47(3):321-2. doi: 10.1038/bmt.2011.157. No abstract available.

PMID:
22395763
45.

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.

Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, Ho VT, Weisdorf DJ, Paczesny S.

Blood. 2012 Apr 19;119(16):3854-60. doi: 10.1182/blood-2012-01-403063. Epub 2012 Mar 1.

46.

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE.

Leuk Lymphoma. 2012 Mar;53(3):499-502. doi: 10.3109/10428194.2011.615427. Epub 2011 Oct 24. No abstract available.

47.

Role of ERCP in patients after hematopoietic stem cell transplantation.

Kim HN, Alousi AM, Lee JH, Qiao W, Xiao L, Ross WA.

Gastrointest Endosc. 2011 Oct;74(4):817-24. doi: 10.1016/j.gie.2011.05.033. Epub 2011 Jul 29.

PMID:
21802682
48.

Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.

Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1841-5. doi: 10.1016/j.bbmt.2011.05.018. Epub 2011 May 27.

49.

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA.

Bone Marrow Transplant. 2012 Feb;47(2):212-6. doi: 10.1038/bmt.2011.61. Epub 2011 Mar 21.

50.

Mesenchymal stem cells in ex vivo cord blood expansion.

Robinson SN, Simmons PJ, Yang H, Alousi AM, Marcos de Lima J, Shpall EJ.

Best Pract Res Clin Haematol. 2011 Mar;24(1):83-92. doi: 10.1016/j.beha.2010.11.001. Epub 2011 Feb 23. Review.

Supplemental Content

Loading ...
Support Center